Pfizer License Agreement: upfront cash payment and issuance of Series B convertible preferred stock to Pfizer, with future contingent payments and royalties
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Thomas Civik
Also a director
Chief Executive Officer
Title from the Form 8-K dated Sep 4, 2026
|
57 | Not stated | Not reported | |
|
Jitendra Wadhane
Principal Financial and Accounting Officer
|
45 |
Since 2025
1 year
|
$766,752 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Sep 8, 2026
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Pfizer License Agreement: upfront cash payment and issuance of Series B convertible preferred stock to Pfizer, with future contingent payments and royalties
Amended and Restated License Agreement with Pfizer: issuance of common stock and a cash payment to Pfizer
University License Agreement and sponsored research agreement; company issued shares and owes milestones, royalties and sublicensing payments
Loading...